Bial R&D Investments, S.A. clinical trials
A subsidiary of Bial - Portela C S.A.
The registry lists 3 studies whose lead sponsor is Bial R&D Investments, S.A.. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Aug 10, 2026.
Registry sponsor names on this page
- Bial R&D Investments, S.A.3 studies
Something wrong with this grouping? Tell us on the Bial - Portela C S.A. page.
Studies
Recruiting first, then most recently updated. Showing 3 of 3. All Bial - Portela C S.A. studies →
- Compassionate Use for BIA 28-6156 in Patients With Parkinson's Disease (PD) Who Have a Pathogenic Variant in the GBA1 Gene (GBA-PD) and Completed the ACTIVATE StudyNo longer availableNCT07522606
Sponsor listed in the registry: Bial R&D Investments, S.A.
- Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in GBA-PDActive, not recruitingNCT05819359Phase 2
Sponsor listed in the registry: Bial R&D Investments, S.A.
- Mass Balance Recovery and Metabolite Identification of Carbon-14 BIA 28-6156CompletedNCT05220072Phase 1
Sponsor listed in the registry: Bial R&D Investments, S.A.